Fauci To Present New Insights Into HIV Latency At 12th World AIDS Conference

During the past year, scientists have shown that HIV persists in a latent form within a relatively small number of resting CD4+ T cells, even in patients who have received prolonged combination antiretroviral therapy and have no readily detectable virus in their blood. Latently infected CD4+ T cells are potential sources of new viral replication if a patient stops therapy, and pose a formidable obstacle to the goal of eradicating HIV from a person's body, particularly if drug resistance develops.

New data show that latent pools of infected cells are established very early in the course of HIV infection, even if a patient is treated expeditiously with highly active antiretroviral therapy ("HAART" - generally a three- or four-drug combination that includes a protease inhibitor). Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) and chief of the NIAID Laboratory of Immunoregulation (LIR), will present these and other new findings at the 12th World AIDS Conference in Geneva, Switzerland.

"We have shown that initiating HAART as soon as 10 days after the onset of the symptoms of acute HIV infection does not prevent the formation of a latent reservoir of virus," says Dr. Fauci. "By the time high levels of HIV are detectable in the blood, the virus probably has spread to the lymphoid organs and established a pool of latently infected cells.

"Our group and others are pursuing studies to identify and treat people recently exposed to HIV, before the burst of virus replication, which occurs in most patients soon after infection. Such studies will help determine whether it will be possible to prevent the early establishment of latent pools of HIV."

In Geneva, Dr. Fauci also will discuss the potential for diminishing latent pools of HIV - the possibility of "flushing out" the virus (at least in the test tube) - by stimulating latently infected CD4+ T cells with antibodies to the CD3 molecule on the cell

Contact: Greg Folkers
(301) 496-2263
NIH/National Institute of Allergy and Infectious Diseases

Page: 1 2 3

Related biology news :

1. Fauci: New Findings Help Explain "Rebound" Of HIV In Patients Who Discontinue Triple-Drug Therapy
2. Wiley publishes Welcome to the Genome: A Users Guide to the Genetic Past, Present, and Future
3. Presentation of Dr. Ingo Potrykus July 21 in Providence
4. Renowned Prostate Cancer Experts Present Latest Findings At UCSF Cancer Center Symposium
5. Echinacea Symposium Presents New Research On Chernobyl Victims
6. Cedars-Sinai Medical Center Physicians And Scientists Present Findings At Annual Meeting Of The Pediatric Academic Societies
7. Virginia Tech Research Group Presents Improved Dental Materials
8. Nations Leading Biomedical Researchers Present Breakthroughs in Liver Disease
9. USGS To Present Diverse Research At ESA Annual Meeting
10. Chern Memorial Award Presented To Wistar Institute Postdoctoral Fellow
11. Neurons Control Brain Immunity: Neurotrophins As Regulators Of Antigen-Presentation In Microglial Cells

Post Your Comments:

(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... announced that Google has adopted the Synaptics ® ... solutions to power its newest flagship smartphones, the Nexus ... --> --> ... to provide strategic collaboration in the joint development of ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/zl6bz4/global_voice ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... DIEGO , Nov. 24, 2015 Halozyme Therapeutics, Inc. ... Healthcare Conference in New York on Wednesday, ... Helen Torley , president and CEO, will provide a corporate ... New York at 1:00 p.m. ET/10:00 a.m. PT ... and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
Breaking Biology Technology:
Cached News: